MCID: PLS003
MIFTS: 21

Plasmacytic Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Plasmacytic Leukemia

MalaCards integrated aliases for Plasmacytic Leukemia:

Name: Plasmacytic Leukemia 12 15
Leukemia, Plasma Cell 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9513
ICD10 33 C90.1 C90.10
ICD9CM 35 203.1
MeSH 44 D007952
NCIt 50 C3180
UMLS 73 C0023484

Summaries for Plasmacytic Leukemia

MalaCards based summary : Plasmacytic Leukemia, also known as leukemia, plasma cell, is related to plasma cell leukemia and leukemia. An important gene associated with Plasmacytic Leukemia is FUT2 (Fucosyltransferase 2). The drugs Doxorubicin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, b cells and kidney.

Related Diseases for Plasmacytic Leukemia

Diseases related to Plasmacytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 plasma cell leukemia 11.7
2 leukemia 9.9

Symptoms & Phenotypes for Plasmacytic Leukemia

Drugs & Therapeutics for Plasmacytic Leukemia

Drugs for Plasmacytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
3
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
4
Lenograstim Approved, Investigational Phase 1, Phase 2,Phase 2 135968-09-1
5
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
6
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
7
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
8
Fludarabine Approved Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
9
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
10
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
11
Allopurinol Approved Phase 2 315-30-0 2094
12
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
13
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
15
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
16
Acetaminophen Approved Phase 2 103-90-2 1983
17
Everolimus Approved Phase 2 159351-69-6 6442177
18
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
19
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
20
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
21
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
22
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
23
Promethazine Approved, Investigational Phase 2 60-87-7 4927
24
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
26
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
27 Pomalidomide Approved Phase 2 19171-19-8
28 Ixazomib Approved, Investigational Phase 2,Phase 1 1072833-77-2
29
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 32326 21704
30
Daratumumab Approved Phase 2 945721-28-8
31
Pegaspargase Approved, Investigational Phase 2 130167-69-0
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 77-92-9 311
33
Glycine Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 56-40-6 750
34 tannic acid Approved, Nutraceutical Phase 2
35
Doxil Approved June 1999 Phase 2 31703
36 Dexamethasone acetate Phase 2,Phase 1 1177-87-3
37 interferons Phase 2
38 glucocorticoids Phase 2,Phase 1
39
protease inhibitors Phase 2,Phase 1
40 Gastrointestinal Agents Phase 2,Phase 1
41 HIV Protease Inhibitors Phase 2,Phase 1
42 Topoisomerase Inhibitors Phase 2,Phase 1
43 Hormone Antagonists Phase 2,Phase 1
44 Hormones Phase 2,Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 2,Phase 1
47 Anti-Bacterial Agents Phase 2,Phase 1
48 Antibiotics, Antitubercular Phase 2,Phase 1
49 Immunoglobulin A Phase 2
50 Antiemetics Phase 2,Phase 1

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
2 Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Unknown status NCT01435720 Phase 1, Phase 2
3 Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
4 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 Completed NCT02858999 Phase 2 PAD-VCD
5 Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Completed NCT00307086 Phase 2 Bortezomib;Melphalan
6 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
7 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
8 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
9 Allo HSCT Using RIC for Hematological Diseases Recruiting NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
10 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Recruiting NCT03314974 Phase 2
11 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
12 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
13 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
14 MUK Nine b: OPTIMUM Treatment Protocol Not yet recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
15 Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
16 Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Terminated NCT00837200 Phase 2 Oncaspar, Doxil, Decadron
17 Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma Terminated NCT01658904 Phase 1, Phase 2 Carfilzomib;Melphalan;Filgrastim
18 Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
19 A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01248923 Phase 1 ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Dexamethasone, steroid; oral;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
20 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin
21 Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Recruiting NCT02504359 Phase 1 Carmustine;Cytarabine;Etoposide;Ixazomib Citrate;Melphalan;Methotrexate;Tacrolimus
22 SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Recruiting NCT02334865 Phase 1 Lenalidomide
23 MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting NCT03031730 Phase 1 Carfilzomib;Dexamethasone;Lenalidomide;MDM2 Inhibitor AMG-232
24 Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Active, not recruiting NCT01372540 Phase 1 Arry-520;Carfilzomib;Dexamethasone;Filgrastim
25 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies Active, not recruiting NCT00988013 Phase 1
26 Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma Withdrawn NCT02315157 Phase 1 Bendamustine
27 High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT03389347 Not Applicable
28 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Recruiting NCT01962636 Not Applicable Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil

Search NIH Clinical Center for Plasmacytic Leukemia

Cochrane evidence based reviews: leukemia, plasma cell

Genetic Tests for Plasmacytic Leukemia

Anatomical Context for Plasmacytic Leukemia

MalaCards organs/tissues related to Plasmacytic Leukemia:

41
Bone, B Cells, Kidney, Bone Marrow

Publications for Plasmacytic Leukemia

Articles related to Plasmacytic Leukemia:

# Title Authors Year
1
ACUTE PLASMACYTIC LEUKEMIA WITH HYPERCALCEMIA. REPORT OF A CASE WITHOUT BONE LESIONS. ( 14255352 )
1965
2
Plasmacytic leukemia; report of a case. ( 14780368 )
1950

Variations for Plasmacytic Leukemia

Expression for Plasmacytic Leukemia

Search GEO for disease gene expression data for Plasmacytic Leukemia.

Pathways for Plasmacytic Leukemia

GO Terms for Plasmacytic Leukemia

Sources for Plasmacytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....